Trial Profile
Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Prednisone; Vincristine
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 28 Jun 2016 Results of cohort of a patients with indolent lymphoma who received initial induction chemo with cyclophosphamide, vincristine, and prednisone (n=387) published in the Cancer
- 02 Feb 2010 Planned end date (1 May 2006) added as reported by ClinicalTrials.gov (NCT00003204).
- 20 May 2009 Lead trial investigator (Horning SJ) added as reported by ClinicalTrials.gov.